La Jolla Pharmaceutical Co. | Mutual Funds
Mutual Funds that own La Jolla Pharmaceutical Co.
SPDR S&P Biotech ETF
1,222,438
4.66%
3,144
0.48%
09/06/2018
Fidelity Select Biotechnology Portfolio
1,189,798
4.54%
0
0.3%
07/31/2018
Prudential Jennison Health Sciences Fund
886,745
3.38%
0
0.8%
07/31/2018
Prudential Jennison Small Company Fund, Inc.
883,259
3.37%
-15,404
0.54%
07/31/2018
Fidelity Series Small Cap Opportunities Fund
705,900
2.69%
142,600
0.25%
04/30/2018
Fidelity Advisor Biotechnology Fund
549,413
2.1%
201,313
0.44%
07/31/2018
Vanguard Total Stock Market Index Fund
515,623
1.97%
0
0%
07/31/2018
Fidelity Select Health Care Portfolio
500,000
1.91%
0
0.15%
07/31/2018
473,062
1.8%
4,700
3.45%
05/31/2018
Pictet - Biotech
450,610
1.72%
98,734
0.66%
03/31/2018
| Address |
4550 Towne Centre Court
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.lajollapharmaceutical.com |
| Updated |
07/08/2019 |
| La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. LJPC-501 is the proprietary formulation for angiotensin II. |
